MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS

Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients...

Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS

A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results...
On location

Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia Vera

PTG-300, a hepcidin mimetic, eliminated the need for phlebotomy and the resultant iron deficiency in patients with high- and low-risk polycythemia vera (PV), according...
On location

Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS

More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Jacqueline Garcia, MD, discusses results from a phase Ib study evaluating venetoclax and azacitidine in patients with treatment-naïve high-risk myelodysplastic syndromes.

Optimizing Outcomes With Azacitidine Treatment in Patients With MDS

Delays in treatment with azacitidine predicted lower survival rates in patients with myelodysplastic syndromes (MDS), independently of the International Prognostic Scoring System (IPSS) score...

Evaluating the TP53 State and Its Implications for Myelodysplastic Syndromes Outcomes

In a new study published in Nature Medicine, researchers evaluated the effect of the TP53 allelic state on the clinical presentation and outcomes of...

Short Telomere Length Increases Non-Relapse Mortality Risk After Allogeneic Transplant for MDS

According to research published in Blood, shorter telomere length was an independent risk factor for non-relapse mortality (NRM) and overall survival (OS) in patients...

Current Issue

January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.

Block title